Allay Therapeutics
San Jose, US · Founded 2016 · Delaware corporation · 30 employees on LinkedIn · 5 known investors
Allay Therapeutics develops localized pain management technology designed to deliver several weeks of post-surgical pain relief. The company focuses on supporting patients through recovery following surgery.
Founders & leadership
AG
Adam GridleyExecutive
KH
Kristen HowellsExecutive
JM
Josh MakowerNamed on SEC filing
TC
Tak CheungNamed on SEC filing
KD
Karun D. NagaNamed on SEC filing
Board
LR
Leighton ReadBoard director
NV
MA
TL
Tiffany LeBoard director
PM
JL
J.C. LopezBoard director
AT
Anselm TanBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$162.6M disclosed across 4 rounds · 2019–2025
▶$45MraisedFeb 2025 · 18 investors · BiotechnologyRule 506(b)
▶$45MraisedFeb 2025 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Leighton ReadDirector
- Mark DeemDirector
- Nicole VitulloDirector
- Michael A. CarusiDirector
- Tiffany LeDirector
- Adam GridleyExecutive Officer, Director
- Paul McCreadieDirector
- J.C. LopezDirector
- Anselm TanDirector
- Kristen HowellsExecutive Officer
- Offering amount
- $60M
- Amount sold
- $45M
- Minimum investment
- $1
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$86.9MraisedDec 2023 · 22 investors · BiotechnologyRule 506(b)
▶$86.9MraisedDec 2023 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tak CheungDirector
- Josh MakowerDirector
- Michael A. CarusiDirector
- Paul McCreadieDirector
- Nicole VitulloDirector
- Adam GridleyExecutive Officer, Director
- Leighton ReadDirector
- Mark DeemDirector
- Offering amount
- $86.9M
- Amount sold
- $86.9M
- Minimum investment
- $1
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedJul 2021 · 7 investors · Other TechnologyRule 506(b)
▶$15MraisedJul 2021 · 7 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Tak CheungDirector
- Josh MakowerDirector
- Mark DeemDirector
- Leighton ReadDirector
- Michael A. CarusiDirector
- Adam GridleyExecutive Officer, Director
- Karun D. NagaDirector
- Offering amount
- $18M
- Amount sold
- $15M
- Minimum investment
- $1
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$15.8MraisedFeb 2019 · 14 investors · Other TechnologyRule 506(b)
▶$15.8MraisedFeb 2019 · 14 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Josh MakowerDirector
- Hanson S. Gifford IIIDirector
- Tak CheungDirector
- Leighton ReadDirector
- Michael A. CarusiDirector
- Mark DeemExecutive Officer, Director
- Karun D. NagaExecutive Officer, Director
- Offering amount
- $28.8M
- Amount sold
- $15.8M
- Minimum investment
- $1
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Allay Therapeutics went on to found or lead other companies.
Competitors · 5
by search overlap
Alloy9 shared keywordsAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.
Lealtx8 shared keywordsLeal Therapeutics develops first-in-class neuro-metabolic therapeutics for central nervous system disorders, including oral small molecules and antisense oligonucleotides targeting metabolic pathways underlying neuropsychiatric and neurodegenerative diseases such as schizophrenia, ALS, and Alzheimer's. Its pipeline includes GLS1 and SPT inhibitors and a delivery platform designed to transport therapeutics across the blood-brain barrier.
Coya Therapeutics6 shared keywords
Relay5 shared keywordsRelay Therapeutics develops small-molecule therapeutics using its Dynamo platform, which combines experimental and computational methods to model protein motion and target proteins considered difficult to drug. Its pipeline focuses on precision oncology and genetic disease.
Nasdaq Private Market5 shared keywordsNasdaq Private Market operates infrastructure for private-company securities, offering liquidity programs (tender offers, buybacks, auctions), a secondary marketplace for accredited investors to buy and sell pre-IPO shares and funds, market data and intelligence, patented settlement technology, and capital-raising solutions. It serves private companies, employee shareholders, institutional and individual investors, and banks/brokers.
Companies competing with Allay Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Allay Therapeutics do?
- Allay Therapeutics develops localized pain management technology designed to deliver several weeks of post-surgical pain relief. The company focuses on supporting patients through recovery following surgery.
- Who are Allay Therapeutics's investors?
- Allay Therapeutics's investors include Arboretum Ventures, Lightstone Ventures, New Enterprise Associates (NEA), SGInnovate, ClavystBio.
- How much funding has Allay Therapeutics raised?
- Allay Therapeutics has disclosed $162.6M raised across 4 rounds.
- Where is Allay Therapeutics headquartered?
- Allay Therapeutics is headquartered in San Jose, US.